FDA accepts for review a new sBLA for Keytruda in NSCLC
8 March 2016 | By Victoria White
The FDA has accepted for review a new supplemental Biologics License (sBLA) for Merck’s Keytruda (pembrolizumab) to include data from KEYNOTE-010...
List view / Grid view
News
More access to morning after pill in Europe than ever before
8 March 2016 | By Victoria White
New research looks at women's awareness of over-the-counter access to emergency contraceptives in Europe...
AbbVie and Boehringer Ingelheim collaborate on BI 655066
7 March 2016 | By Victoria White
BI 655066 is an anti-IL-23 monoclonal biologic antibody being evaluated in psoriasis, Crohn’s disease, psoriatic arthritis and asthma...
SMC accepts three medicines for use in NHS Scotland; rejects two
7 March 2016 | By Victoria White
The Scottish Medicines Consortium (SMC) has accepted three new medicines for routine use in NHS Scotland.
New data for Enstilar foam spray presented at AAD
7 March 2016 | By Victoria White
These data show the enhanced local bioavailability of calcipotriol/betamethasone dipropionate in the foam spray vehicle results from supersaturation...
FSA grants Fast Track designation for MEDI8852
7 March 2016 | By Victoria White
MedImmune has received Fast Track designation from the FDA for MEDI8852 for the treatment of patients hospitalised with Type A strain influenza...
CPhI South East Asia opens as Indonesia encourages foreign investment
7 March 2016 | By CPhI
CPhI South East Asia, organised by UBM EMEA, will take place at the Jakarta International Expo, Indonesia, from 6th-8th April 2016...
Cosentyx superior to Stelara in achieving sustained skin clearance in psoriasis
New late-breaking data from Novartis’ head-to-head CLEAR study demonstrates that Cosentyx (secukinumab) remains superior to Stelara (ustekinumab) in achieving sustained skin clearance (PASI 90 response) at 52 weeks for adults living with moderate-to-severe psoriasis.
Study shows Victoza reduces the risk of major adverse cardiovascular events
4 March 2016 | By Victoria White
Victoza (liraglutide) was studied over a period of up to 5 years in more than 9,000 adults with type 2 diabetes at high risk of major adverse cardiovascular events...
First patient dosed in BAX 826 haemophilia A Phase I trial
4 March 2016 | By Victoria White
BAX 826 is a next-generation rFVIII treatment based on the full length Advate that uses proprietary polysialic acid technology to extend its circulating half-life...
DiscoverX and the SGC partner to make an annotated collection of >600 kinase inhibitors freely available
4 March 2016 | By DiscoverX
DiscoverX Corporation announced its partnership with the Structural Genomics Consortium (SGC)...
Peter J. Arduini elected to the board of Bristol-Myers Squibb
4 March 2016 | By Victoria White
Mr. Arduini is currently president and chief executive officer and director of Integra LifeSciences, a leading global medical technology company...
Phase I/II data for neoGAA in Pompe disease presented
4 March 2016 | By Victoria White
Sanofi Genzyme says the safety and efficacy data from the NEO1 study support further development of neoGAA...
Researchers make cancer immunotherapy ‘breakthrough’
4 March 2016 | By Victoria White
Researchers have found the tools necessary to give immunotherapy the precision guidance that patients with cancer so desperately need...
AMRA Profiler to be added to GE Healthcare MRI scanners
3 March 2016 | By Victoria White
AMRA Profiler is a cloud-based body composition measurement service, which uses images from a rapid, 6-minute MRI scan to deliver accurate, precise fat and muscle measurements...
